PKU carrier status: what the newborn heel prick already covers, and what your file adds
PKU is the condition newborn screening was built around: nearly every baby born in Europe or North America since the 1960s has been tested for it within days of birth. That history changes what a carrier result is for, and it is worth understanding before you read one.
Also known as: PAH carrier, PKU, hyperphenylalaninemia.
- Gene
- PAH
- Inheritance
- Autosomal recessive
- Carrier frequency
- roughly 1 in 50 in many European populations; varies by ancestry
What it is
Phenylketonuria is caused by changes in PAH, the gene for phenylalanine hydroxylase. That liver enzyme converts phenylalanine, an amino acid in ordinary dietary protein, into another one, tyrosine. When both copies of PAH carry a disease-causing change, the conversion fails, phenylalanine accumulates, and the developing brain is harmed: untreated classic PKU causes severe, irreversible intellectual disability. Caught in the first days of life and managed with a strict low-phenylalanine diet, children with PKU develop normally, and newer treatments help a subset of patients further. Severity runs on a spectrum, because some PAH changes leave the enzyme partly working: the mildest raise phenylalanine a little without needing treatment at all.
The reason nearly everyone has been tested for it is Robert Guthrie's blood-spot test from the early 1960s, the first mass newborn screen, whose descendant is the heel-prick card still collected in maternity wards today. Screening works because the disease is invisible at birth and treatable only if caught before symptoms: exactly the case where a biochemical test on every newborn beats waiting. In Europe roughly one baby in 4,000 to 10,000 is born with PKU, with strong local variation, and because screening finds them in time, the untreated disease has nearly vanished from the countries that screen.
How it is inherited
PKU is autosomal recessive. A carrier has one changed copy of PAH and one working copy, and the working copy makes enough enzyme, so carriers process phenylalanine normally and are healthy. The result matters jointly: when both partners in a couple are carriers, each pregnancy has a one in four chance of a child with PKU. When only one partner is a carrier, no child can be affected, so the useful next step after a carrier finding is testing the partner, not more tests on yourself.
Two distinctions save confusion here. First, which two changes a child inherits shapes the outcome, since PAH changes range from complete loss of the enzyme to nearly none, which is why the condition spans classic PKU to mild raised phenylalanine. Second, maternal PKU is about affected mothers, not carriers: a woman who herself has PKU must control her phenylalanine before and during pregnancy, because high levels harm the fetus regardless of the baby's own genes. A carrier is not in that situation. Her single changed copy raises no phenylalanine and calls for no diet.
What your raw DNA file can and cannot tell you
Start with the chip file. PAH is one of the genes consumer arrays genuinely put on the typed list, and a positive call at a listed position is a real signal worth confirming with a clinician. The quiet result is the weak half. Hundreds of disease-causing PAH changes are known, most of them rare, and an array that typed a handful of the common ones has said nothing about the rest. The further your ancestry sits from the populations the list was tuned to, the less a quiet readout means. Aimosti does not report carrier status from a chip file, for this gene or any other, and says so rather than returning a reassuring blank.
A whole-genome VCF or gVCF is what our carrier module reads, and it can find PAH changes anywhere the sequencing covered rather than only at pre-chosen positions. Its limits are worth stating just as plainly. A short-variant file does not represent large deletions or duplications, which are among the known PAH alleles, so a clear result lowers the odds that you are a carrier without taking them to zero. And a small minority of raised-phenylalanine conditions involve other genes in the same pathway, so PAH is most of the biochemical story rather than all of it.
This product is not carrier screening, and PKU is the clearest illustration in this whole family of why that distinction is easy to live with. Whatever any file says about any parent, the newborn screen measures phenylalanine itself in the baby's blood a few days after birth, works whatever the underlying change, and is how affected children are actually found and treated in time. Carrier information earns its keep earlier, before a pregnancy, when a couple still has room to decide what to do with it. If the answer matters at that stage, a validated carrier test of both partners, read with a genetic counselor, is the tool built for the job.
A genotyping chip reads only a few hundred thousand pre-selected positions, about 0.02% of your genome, chosen for common variation. It does not sequence the rest, so it cannot find the rare or novel pathogenic variants the clinical and carrier modules look for: a “no finding” from chip data means “this chip never looked”, far more so than with whole-genome sequencing. Chip data suits common-variant traits, pharmacogenomic tag SNPs, and haplogroup ancestry, not clinical or carrier screening.
Common questions
Can 23andMe or AncestryDNA tell me if I am a PKU carrier?
Partially. PKU is on the carrier lists the major array vendors screen, so some PAH changes genuinely are typed, and a positive call there is worth confirming with a clinician. A quiet result is much weaker: it covers only the listed positions, while hundreds of PAH changes are known, so it is not a rule-out for anyone and means least for ancestries the list was not tuned to. Aimosti does not report carrier status from chip files.
Every baby is already screened for PKU at birth. Why would carrier status matter?
Because the two tests answer different questions at different times. The heel prick finds an affected baby days after birth, early enough to treat. Carrier testing moves the information before a pregnancy, when a couple can find out whether the one-in-four scenario applies to them at all and decide what, if anything, to do about it. Screening after birth is the safety net; carrier knowledge is the advance notice.
My file shows a PAH variant. Does it affect my own health?
In the ordinary case, no. One working copy of PAH makes enough enzyme, and carriers process phenylalanine normally, with no diet to follow and nothing to monitor. The separate situation people sometimes mix this up with is maternal PKU, which concerns women who themselves have the condition, with two changed copies: they must control phenylalanine before and during pregnancy. A carrier result does not put you in that group.
Why is PKU so rare in Finland?
Population history. Finland has the lowest PKU incidence in Europe, around one case per 100,000 births against one in 4,000 to 10,000 elsewhere on the continent. The same founder history that concentrated the Finnish Disease Heritage conditions in this population happened to leave disease-causing PAH changes out, so Finnish-ancestry readers start with unusually low carrier odds, and a chip list tuned to other populations says even less here than usual. Low is not zero, though: rare carriers exist in every population.